TNFSF10 and prostate carcinoma: The HDAC inhibitors romidepsin and MS-275 increased the effects of adenoviral TRAIL gene therapy on castration-sensitive LNCaP prostate cancer cells without toxicity to non-malignant prostate epithelial cells[69].